odanacatib: Clinical Trials

6 trials of odanacatib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 2 withdrawn. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Completed 2, Terminated 2, Withdrawn 2

Follow odanacatib: new trials by email Literature Review of odanacatib trials Research Report on odanacatib

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
odanacatib, placebo to odanacatib - Osteoporosis
Phase 3TerminatedMerck Sharp & Dohme LLC1352013-03-142019-09-04
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
Odanacatib, Alendronate, Placebo (odanacatib) - Osteoporosis, Postmenopausal Osteoporosis
Phase 3WithdrawnMerck Sharp & Dohme LLC2012-05-012015-08-27
A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)
Odanacatib, Placebo for Odanacatib, Vitamin D3 - Osteoporosis
Phase 3CompletedMerck Sharp & Dohme LLC2942010-06-092018-08-28
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
Odanacatib, Placebo, Vitamin D3 - Osteoporosis
Phase 3CompletedMerck Sharp & Dohme LLC2142008-10-022018-08-27
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
odanacatib, placebo (unspecified) - Prostate Cancer
Phase 3WithdrawnMerck Sharp & Dohme LLC2008-09-012016-08-12
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
Odanacatib, Placebo for Odanacatib, Vitamin D3 - Postmenopausal Osteoporosis
Phase 3TerminatedMerck Sharp & Dohme LLC160712007-09-132024-06-11

Conditions studied

Osteoporosis (4)  ·  Osteoporosis, Postmenopausal (2)  ·  Prostatic Neoplasms (1)

Sponsors

Merck Sharp & Dohme LLC (6)

Results publications

PMID 23337728, PMID 24898537, PMID 31676222, PMID 32119749, PMID 33200257, PMID 33724542, PMID 35711006